ImmunityBio, Inc. (IBRX)

8.06 +0.14 (+1.77%) At close: 04:00PM EDT

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
844 696 5235
https://immunitybio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 628

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.	Executive Chairman of the Board and Global Chief Scientific & Medical Officer	865.34k	N/A	1953
Mr. Richard Gerald Adcock	President, CEO & Director	1.16M	N/A	1969
Mr. David C. Sachs	Chief Financial Officer	824.62k	N/A	1978
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director	N/A	N/A	1965
Dr. Leonard S. Sender M.D.	Chief Operating Officer	N/A	N/A	N/A
Ms. Regan J. Lauer	Chief Accounting Officer	N/A	N/A	1970
Dr. Enrique Diloné Ph.D., RAC	Chief Technology Officer	N/A	N/A	1967
Mr. Jason R. Liljestrom	General Counsel & Corporate Secretary	N/A	N/A	1983
Ms. Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	N/A	N/A	N/A
Dr. Sandeep K. Reddy M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Corporate Governance

ImmunityBio, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.